Bank Julius Baer & Co. Ltd Zurich Purchases 1,294 Shares of Veeva Systems Inc. (NYSE:VEEV)

Bank Julius Baer & Co. Ltd Zurich boosted its position in Veeva Systems Inc. (NYSE:VEEV) by 1.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 79,771 shares of the technology company’s stock after purchasing an additional 1,294 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich’s holdings in Veeva Systems were worth $17,919,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Cardinal Capital Management grew its stake in shares of Veeva Systems by 0.3% during the fourth quarter. Cardinal Capital Management now owns 15,727 shares of the technology company’s stock worth $3,307,000 after acquiring an additional 44 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. grew its stake in shares of Veeva Systems by 1.2% during the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,307 shares of the technology company’s stock worth $904,000 after acquiring an additional 50 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its stake in shares of Veeva Systems by 72.5% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 119 shares of the technology company’s stock worth $25,000 after acquiring an additional 50 shares during the last quarter. Patriot Financial Group Insurance Agency LLC boosted its position in Veeva Systems by 0.7% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 6,975 shares of the technology company’s stock valued at $1,467,000 after buying an additional 51 shares during the last quarter. Finally, CHICAGO TRUST Co NA boosted its position in Veeva Systems by 2.9% in the fourth quarter. CHICAGO TRUST Co NA now owns 1,880 shares of the technology company’s stock valued at $395,000 after buying an additional 53 shares during the last quarter. 88.20% of the stock is currently owned by institutional investors.

Veeva Systems Stock Performance

Shares of VEEV stock opened at $247.10 on Friday. The stock’s fifty day moving average is $224.92 and its two-hundred day moving average is $220.21. The firm has a market capitalization of $40.12 billion, a P/E ratio of 61.01, a PEG ratio of 1.89 and a beta of 0.88. Veeva Systems Inc. has a fifty-two week low of $170.25 and a fifty-two week high of $258.93.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Robert W. Baird upped their target price on Veeva Systems from $283.00 to $285.00 and gave the company an “outperform” rating in a research report on Thursday. Citigroup upped their target price on Veeva Systems from $281.00 to $307.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Stephens reiterated an “overweight” rating and issued a $280.00 target price on shares of Veeva Systems in a research report on Thursday. StockNews.com upgraded Veeva Systems from a “hold” rating to a “buy” rating in a research report on Monday, February 17th. Finally, Truist Financial upped their price objective on Veeva Systems from $210.00 to $217.00 and gave the stock a “hold” rating in a research report on Thursday. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $255.28.

Veeva Systems Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.